164 related articles for article (PubMed ID: 38693813)
21. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia.
Salsman JM; Beaumont JL; Wortman K; Yan Y; Friend J; Cella D
Support Care Cancer; 2015 May; 23(5):1355-64. PubMed ID: 25351456
[TBL] [Abstract][Full Text] [Related]
22. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
23. Appetite and food intake results from phase I studies of anamorelin.
Blum RA; Mair S; Duus EM
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1027-1035. PubMed ID: 31074178
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.
Currow DC; Maddocks M; Cella D; Muscaritoli M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400622
[TBL] [Abstract][Full Text] [Related]
25. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.
Currow DC; Abernethy AP
Future Oncol; 2014 Apr; 10(5):789-802. PubMed ID: 24472001
[TBL] [Abstract][Full Text] [Related]
26. Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database.
Ohta H; Horii T; Yasu T
Oncology; 2023; 101(12):782-785. PubMed ID: 37579746
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
Advani SM; Advani PG; VonVille HM; Jafri SH
BMC Cancer; 2018 Nov; 18(1):1174. PubMed ID: 30482179
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia.
Tsukiyama I; Iwata T; Takeuchi T; Kato RI; Sakuma M; Tsukiyama S; Kato M; Ikeda Y; Ohashi W; Kubo A; Mori N
Support Care Cancer; 2023 Oct; 31(12):621. PubMed ID: 37815652
[TBL] [Abstract][Full Text] [Related]
29. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
Terauchi Y; Usami M; Inoue T
Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
[TBL] [Abstract][Full Text] [Related]
30. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study.
Iwai N; Sakai H; Oka K; Sakagami J; Okuda T; Hattori C; Taniguchi M; Hara T; Tsuji T; Komaki T; Kagawa K; Doi T; Ishikawa T; Yasuda H; Itoh Y
Support Care Cancer; 2023 Jan; 31(2):115. PubMed ID: 36640181
[TBL] [Abstract][Full Text] [Related]
31. Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.
Hoon SN; Fyfe K; Peddle-McIntyre CJ; Bowyer S; Hawkins F; Jeffery E; Chih HJ; Creaney J; Nowak A; Brims F
BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32213537
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
[TBL] [Abstract][Full Text] [Related]
33. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis.
Taniguchi J; Mikura S; da Silva Lopes K
Sci Rep; 2023 Sep; 13(1):15257. PubMed ID: 37709824
[TBL] [Abstract][Full Text] [Related]
35. [The Treatment of Cancer Cachexia].
Tanaka S; Takayama K
Gan To Kagaku Ryoho; 2021 Aug; 48(8):987-991. PubMed ID: 34404062
[TBL] [Abstract][Full Text] [Related]
36. Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Malik JS; Yennurajalingam S
Ann Palliat Med; 2019 Jan; 8(1):80-85. PubMed ID: 30525771
[TBL] [Abstract][Full Text] [Related]
37. Anamorelin Induced Acute Hyperglycemia in a Patient with Advanced Pancreatic Cancer and Diabetes: A Case Report.
Yamamoto J; Onodera H; Kaminaga Y; Kayaba Y; Usui M
Tohoku J Exp Med; 2024 May; 262(4):263-268. PubMed ID: 38325830
[TBL] [Abstract][Full Text] [Related]
38. Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.
Dev R; Amano K; Naito T; Del Fabbro E
Curr Oncol Rep; 2024 May; ():. PubMed ID: 38771469
[TBL] [Abstract][Full Text] [Related]
39. The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials.
Rezaei S; de Oliveira LC; Ghanavati M; Shadnoush M; Akbari ME; Akbari A; Hadizadeh M; Ardehali SH; Wakabayashi H; Elhelali A; Rahmani J
J Oncol Pharm Pract; 2023 Oct; 29(7):1725-1735. PubMed ID: 37525932
[TBL] [Abstract][Full Text] [Related]
40. [Future Prospects of Cancer Cachexia].
Morita-Tanaka S; Takayama K
Gan To Kagaku Ryoho; 2022 Jul; 49(7):719-722. PubMed ID: 35851337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
